Annovis Bio, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 13, 2026, disclosing a net loss of $9,462,136 for the third quarter and an accumulated deficit of $205,592,992.
Key Highlights
- Q3 2026 net loss: $9,462,136, compared to $7,262,658 in Q3 2025, according to the filing.
- Nine-month net loss: $41,889,333 for the nine months ended September 30, 2026, versus $19,019,785 for the same period in 2025.
- Cash position: Cash and cash equivalents fell to $2,819,898 as of September 30, 2026, down from $19,532,338 at December 31, 2025.
- Shares outstanding: 42,686,201 shares of common stock were issued and outstanding as of September 30, 2026, up from 27,199,139 at December 31, 2025; 62,022,520 shares were outstanding as of November 13, 2026.
- Stockholders' deficit: Total stockholders' deficit was $(13,233,825) at September 30, 2026, compared to positive equity of $16,851,250 at December 31, 2025.
- Warrant liability: The warrant liability increased to $12,473,000 at September 30, 2026, from $595,000 at December 31, 2025.
- R&D expenses: Research and development expenses were $15,780,102 for Q3 2026, compared to $6,291,171 for Q3 2025.
Annovis Bio's Financial Position and Operations for the Quarter Ended September 30, 2026
According to the filing, Annovis Bio (NYSE:ANVS) reported a net loss of $9,462,136 for the three months ended September 30, 2026, driven primarily by total operating expenses of $16,969,108. Research and development costs of $15,780,102 accounted for the majority of operating expenses in the quarter, up sharply from $6,291,171 in Q3 2025. General and administrative expenses were $1,189,006 for the quarter, compared to $1,143,804 in the prior-year period.
The company reported other income, net, of $7,506,972 for Q3 2026, which included a $7,460,000 gain from the change in fair value of warrants and interest income of $84,868, partially offset by other financing costs of $37,896. For the nine months ended September 30, 2026, the filing disclosed total operating expenses of $49,359,001 and a net loss of $41,889,333, compared to $19,989,109 in operating expenses and a net loss of $19,019,785 for the same period in 2025. The basic and diluted net loss per share for the nine-month period was $(1.16), based on a weighted-average share count of 36,054,066.
The balance sheet reflected significant changes during 2026. Cash and cash equivalents declined to $2,819,898 from $19,532,338 at year-end 2025. The company raised capital through multiple transactions during the period, including issuances under an Equity Distribution Agreement and two registered underwritten offerings in April and May 2026, involving common stock and warrants. The accumulated deficit grew to $205,592,992 at September 30, 2026, from $163,703,659 at December 31, 2025. Total liabilities were $18,737,552, with the warrant liability of $12,473,000 representing a significant non-current component. The company is classified as a non-accelerated filer and a smaller reporting company.
What Was Disclosed
Annovis Bio's 10-Q for Q3 2026 disclosed a net loss of $9,462,136 for the quarter and $41,889,333 for the nine-month period, a sharply reduced cash balance, a growing accumulated deficit of $205,592,992, and a substantially increased warrant liability of $12,473,000.




Please wait processing your request...